CLAIMS

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or isomer thereof,

wherein:

X^1, X^2, and X^3 are independently selected from C-R^1 and N;

Z^1, Z^2, and Z^3 are independently selected from C-R^1 and N;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C_1-C_6)alkyl and optionally substituted -(C_1-C_6)alkoxy;

Y is selected from S, O, and N-R^2, wherein R^2 is selected from -H, and optionally substituted -(C_1-C_6)alkyl;

R^3 is selected from optionally substituted R^4-C(O)-(C_1-C_3)alkyl-, R^4C(O)-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6HC-, and R^5R^6N-;

R^4 is selected from H_2N-, HO-, R^5R^6N-, optionally substituted (C_1-C_{10})alkyl-, optionally substituted (C_1-C_{10})alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C_1-C_6)alkylene-, and optionally substituted heterocycle-(C_1-C_6)alkylene-;

R^5 and R^6 are independently selected from H-, H_2N-, HO-, optionally substituted (C_1-C_{10})alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted R^4C(O)-(C_1-C_{10})alkyl-, R^4C(O)-, R^4-, and substituted amino; or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;

R^7 is selected from H-, and optionally substituted (C_1-C_6)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C_1-C_6)alkyl;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C_1-C_6)alkoxy, -NH_2, substituted amino, optionally substituted -(C_1-C_6)alkyl-NH_2 and optionally substituted -(C_1-C_6)alkyl; and

n is 0, 1, 2, 3, 4, or 5.

~~2. The compound of claim 1, wherein X^1 is N, X^2 is C-H, and X^3 is C-H.~~

~~3. The compound of claim 1, wherein X^1 is C-H, X^2 is C-H, and X^3 is C-H.~~

~~4. The compound of any one of claims 1 to 3, wherein Y is S.~~

~~5. The compound of any one of claims 1 to 4, wherein Z^1 is C-H, Z^2 is C-H, and Z^3 is C-H.~~

~~6~~2. The compound of ~~any one of claims 1 to 5~~claim 1, wherein the compound is of formula (Ia):



(Ia)

wherein:

R^1 is selected from -H, -halogen, optionally substituted -(C_1-C_6)alkyl and optionally substituted -(C_1-C_6)alkoxy;

R^3 is selected from $R^4C(O)$-, $R^4C(O)CH_2$-, R^5R^6N-, and R^5R^6HC-;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted -(C_1-C_6)alkoxy, -NH_2, -NR^5R^6, -CH_2NH_2 and optionally substituted -(C_1-C_6)alkyl; and

n is 0, 1, 2, or 3.

~~7~~3. The compound of claim ~~6~~2, wherein X^1 is N.

~~8~~4. The compound of claim ~~6~~2, wherein X^1 is C-H.

~~9~~5. The compound of any one of claims 1 to ~~8~~4, wherein R^7 is optionally substituted $(C_1\text{-}C_6)$alkyl-.

~~10. The compound of claim 9, wherein R^7 is H_3C -.~~

~~11~~6. The compound of any one of claims 1 to ~~10~~5, wherein R^8 is optionally substituted -$(C_1\text{-}C_6)$alkyl.

~~12. The compound of claim 11, wherein R^8 is $-CH_2CH_3$.~~

~~13~~7. The compound of any one of claims 1 to ~~12~~6, wherein R^9 is -CN.

~~14~~8. The compound of ~~any one of~~ claims ~~2~~1 ~~to 13~~, wherein R^{11} is -halogen.

~~15. The compound of claim 14, wherein R^{11} is -F.~~

~~16~~9. The compound of any one of claims 1 to ~~15~~8, wherein the compound is of formula (Ib):



(Ib)

wherein:

X^1 is C-H or N; and

R^1 is -H, -halogen, or optionally substituted -$(C_1\text{-}C_6)$alkyl and optionally substituted -$(C_1\text{-}C_6)$alkoxy.

~~17~~10. The compound of any one of claims 1 to ~~16~~9, wherein:

a) R^3 is ;

b) R^3 is ;

c) R^3 is ;

d) R^3 is  that is an optionally substituted monocyclic or bicyclic (C_2-C_9)heterocycle-; or

e) R^3 is  that is an optionally substituted monocyclic or bicyclic (C_3-C_8)carbocycle-, or an optionally substituted monocyclic or bicyclic (C_2-C_9)heterocycle-; wherein:

R^4 is selected from HO-, H_2N-, $R^{15}R^{16}N$-, optionally substituted (C_1-C_5)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;

R^{12} is selected from -H, -NH_2, -OH, -$CH_2C(O)R^4$, -$C(O)R^4$, -$CHR^{15}R^{16}$, -$NR^{15}R^{16}$, optionally substituted -(C_1-C_5)alkyl, optionally substituted monocyclic or bicyclic -(C_3-C_8)carbocycle, and an optionally substituted monocyclic or bicyclic -(C_2-C_9)heterocycle; and

R^{13} and R^{14} are independently selected from -H, -$CH_2C(O)R^{17}$, -CH_2R^{17}, -$C(O)R^{17}$, -$R^{18}C(O)R^{17}$, -$CH_2R^{18}C(O)R^{17}$, optionally substituted -(C_1-C_5)alkyl, optionally substituted monocyclic or bicyclic -(C_3-C_8)carbocycle, and an optionally substituted monocyclic or bicyclic -(C_2-C_9)heterocycle, wherein R^{17} and R^{18} are independently selected from optionally substituted -(C_1-C_5)alkyl, optionally substituted monocyclic or bicyclic -(C_3-C_8)carbocycle, and an optionally substituted monocyclic or bicyclic -(C_2-C_9)heterocycle; and

R^{15} and R^{16} are independently selected from H-, optionally substituted (C_2-C_5)heterocycloalkyl-C(O)-, optionally substituted (C_3-C_6) cycloalkyl-C(O)-, optionally

substituted (C_1-C_5)alkyl-, optionally substituted 3- to 10-membered saturated monocyclic heterocycle or carbocycle, and optionally substituted 3- to 10-membered saturated bicyclic heterocycle or carbocycle, wherein the optional substituents are selected from hydroxy, $HOCH_2$-, cyano, halogen, substituted amino, and (C_1-C_5)alkyl; or R^{15} and R^{16} are cyclically linked to form a 3- to 6-membered monocyclic saturated heterocycle, optionally substituted with hydroxy, $HOCH_2$-, cyano, halogen, substituted amino, or (C_1-C_5)alkyl.

~~18~~11. The compound of ~~any one of~~ claim~~s~~ 1~~0 to 17~~, wherein:

R^3 is  or ,

R^4 is selected from R^{32}, $R^{32}HN$-, $R^{32}N(R^{33})$-,and $R^{32}HN$-R^{36}-;

R^{32} and R^{33} are independently selected from H-, optionally substituted (C_1-C_3)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;

R^{36} is selected from optionally substituted (C_1-C_3)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{32}, R^{33} and R^{36} groups are independently selected from -CN, -OH, -CH_2OH, -(C_1-C_3)alkyl, -(C_1-C_3)alkoxy, -(C_3-C_6)cycloalkyl, (C_2-C_5)heterocycloalkyl, and -$N(R^{37})R^{38}$, wherein R^{37} and R^{38} are independently selected from H, (C_1-C_3)alkyl, (C_3-C_6)cycloalkyl, and (C_2-C_5)heterocycloalkyl.

~~19~~12. The compound of claim ~~18~~11, wherein R^4 is selected from:



~~20~~13. The compound of claim ~~19~~12, wherein the compound is selected from:



Compound 11



Compound 12



Compound 13



Compound 14



Compound 15



Compound 16



Compound 47



Compound 48



Compound 49



Compound 50



Compound 51



Compound 52



Compound 53



Compound 54



Compound 55



Compound 56



Compound 57



Compound 58



Compound 59



Compound 60



Compound 61



Compound 62



Compound 63



Compound 64



Compound 65

and



Compound 87

.

~~21~~14. The compound of ~~any one of~~ claims ~~1~~0 ~~to 17~~, wherein:

R^3 is 

R^{14} is selected from R^{34}-, $R^{34}CH_2$-, $R^{34}C(O)R^{35}$-, and $R^{34}C(O)R^{35}CH_2$-;

each R^{34} and R^{35} are independently selected from optionally substituted -(C_1-C_3)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;

the optional substituents of the R^{34} and R^{35} groups are independently selected from -CN, -OH, -CH_2OH, -(C_1-C_3)alkyl, -(C_1-C_3)alkoxy, and -(C_1-C_3)alkyl; and

R^{13} is -H.

~~22~~15. The compound of claim ~~21~~14, wherein R^{14} is selected from:



and

.

~~23~~16. The compound of claim ~~22~~15, wherein the compound is selected from:



Compound 21



Compound 22



Compound 34



Compound 35



Compound 36



Compound 37

–



Compound 38



Compound 39



Compound 40

and



Compound 41

~~24~~17. The compound of ~~any one of~~ claims ~~1~~0 ~~to 17~~, wherein R^3 is



.

~~25~~18. The compound of claim ~~24~~17, wherein R^3 is selected from:



, 

, and 

.

~~26~~19. The compound of claim ~~24~~ 17 or ~~25~~18, wherein:

R^{12} is selected from H-, H_2N-, R^{31}-C(O)-, R^{31}-C(O)CH_2-, R^{31}-NHC(O)-, R^{31}-C(O)NH-, R^{31}-NH-, R^{31}-N(CH_3)C(O)-, R^{31}-C(O)N(CH_3)-, R^{31}-N(CH_3)-, and R^{31}-O- ;

R^{31} is selected from optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$-, (C_1-C_3)alkyl-, (C_1-C_3)alkoxy-, substituted (C_1-C_3)alkyl-, (C_3-C_6)cycloalkyl-, and (C_2-C_5)heterocycloalkyl-.

~~27~~20. The compound of any one of claims ~~24~~ 17 to ~~26~~19, wherein R^{12} is selected from:



and

~~28~~21. The compound of any one of claims ~~24~~ 17 to ~~27~~20, wherein the compound is selected from:



Compound 1



Compound 2



Compound 3



Compound 4



Compound 5



Compound 6



Compound 7



Compound 8



Compound 9



Compound 10



Compound 17



Compound 18



Compound 19



Compound 20



Compound 23



Compound 24



Compound 25



Compound 26



Compound 27



Compound 28



Compound 29



Compound 30



Compound 31



Compound 32



Compound 33



Compound 42



Compound 43



Compound 44



Compound 45



Compound 46



Compound 66



Compound 67



Compound 68



Compound 69



Compound 70



Compound 71



Compound 72



Compound 73



Compound 74



Compound 75



Compound 76



Compound 77



Compound 78



Compound 79



Compound 80



Compound 81



Compound 82



Compound 83



Compound 84



Compound 85



Compound 86



Compound 88



Compound 89



Compound 90



Compound 91



Compound 92



Compound 93



Compound 94



Compound 95



Compound 96



Compound 97



Compound 98



Compound 105



Compound 106



Compound 107



Compound 108



Compound 109



Compound 110



Compound 111



Compound 112



Compound 113



Compound 114



Compound 115



Compound 118



Compound 119



Compound 120



Compound 121



Compound 122



Compound 123



Compound 124



Compound 125



Compound 126

and



Compound 127

.

~~29~~22. The compound of ~~any one of claims 1 to 5~~claim 1, wherein the compound is of formula (Ie):



(Ie)

wherein:

X^1 and X^4 are independently N or C-R^1;

R^1 is selected from H, halogen, optionally substituted -(C_1-C_6)alkyl, and optionally substituted -(C_1-C_6)alkoxy; and

R^{31} is selected from optionally substituted (C_2-C_5)heterocycloalkyl, and optionally substituted (C_3-C_7)cycloalkyl-;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted -(C_1-C_6)alkoxy, -NH_2, -NR^5R^6, -CH_2NH_2 and optionally substituted -(C_1-C_6)alkyl; and

n is 0, 1, 2, or 3.

~~30~~23. The compound of claim ~~29~~22, wherein the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$-, (C_1-C_3)alkyl- (e.g., H_3C-), (C_1-C_3)alkoxy-, substituted (C_1-C_3)alkyl-, and (C_3-C_6)cycloalkyl- (e.g., cyclopropyl).

~~31~~24. The compound of claim ~~29~~ 22 or ~~30~~23, wherein the compound is of formula (If):



(If)

wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2; and

when q is 2, X^5 is NH, O, or CH(OH).

~~32. The compound of any one of claims 29 to 31, wherein R^7 is optionally substituted (C_1-C_6)alkyl.~~

~~33. The compound of claim 32, wherein R^7 is H_3C-.~~

~~34. The compound of any one of claims 29 to 33, wherein R^8 is optionally substituted (C_1-C_6)alkyl.~~

~~35. The compound of claim 34, wherein R^8 is $-CH_2CH_3$.~~

~~36. The compound of any one of claims 29 to 35, wherein R^9 is -CN.~~

~~37. The compound of any one of claims 29 to 36, wherein R^{11} is -halogen.~~

~~38. The compound of claim 37, wherein R^{11} is -F.~~

~~39~~25. The compound of claim ~~24~~ 17 or ~~29~~22, wherein the compound is of formula (Ic):



(Ic)

wherein:

X^1 and X^4 are independently N or C-R^1;

R^1 is selected from H, halogen, optionally substituted -(C_1-C_6)alkyl, and optionally substituted -(C_1-C_6)alkoxy; and

R^{31} is selected from optionally substituted (C_2-C_5)heterocycloalkyl, and optionally substituted (C_3-C_7)cycloalkyl-.

~~40. The compound of claim 39, wherein the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$-, (C_1-C_3)alkyl- (e.g., H_3C-), (C_1-C_3)alkoxy-, substituted (C_1-C_3)alkyl-, and (C_3-C_6)cycloalkyl- (e.g., cyclopropyl).~~

~~41~~26. The compound of claim ~~39~~ 25~~or 40~~, wherein the compound is of formula (Id):



(Id)

wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2; and

when q is 2, X^5 is NH, O, or CH(OH).

~~42. The compound of any one of claims 29 to 41, wherein X^1 is N.~~

~~43. The compound of any one of claims 29 to 41, wherein X^1 is C-H.~~

~~44~~27. The compound of ~~any one of claims 41 to 43~~claim 26, wherein the compound is selected from:



















5





and



.

~~45~~28. The compound of ~~any one of~~ claims ~~1~~0 ~~to 17~~, wherein R^3 is



.

~~46~~29. The compound of claim ~~45~~28, wherein R^3 is



.

~~47~~30. The compound of claim ~~45~~ 28 or ~~46~~29, wherein:

R^{12} is selected from H-, R^{31}-C(O)-, R^{31}-C(O)CH_2-, R^{31}-NHC(O)-, R^{31}-C(O)NH-, R^{31}-N(CH_3)C(O)-, and R^{31}-C(O)N(CH_3) -;

R^{31} is selected from optionally substituted (C_1-C_3)alkyl-, optionally substituted cycloalkyl-, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$-, (C_1-C_3)alkyl-, (C_1-C_3)alkoxy- and substituted (C_1-C_3)alkyl-.

~~48~~31. The compound of ~~any one of~~ claims ~~28~~46 ~~to 47~~, wherein R^{12} is selected from:



.

4932. The compound of ~~any one of~~ claims ~~45 to 48~~, wherein the compound is selected from:



Compound 99



Compound 100



Compound 101



Compound 102



Comopund 103

and



Compound 104

.

5033. A pharmaceutical composition comprising:

a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4932; and

a pharmaceutically acceptable excipient.

~~51. A compound for use in inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49.~~

~~52. A pharmaceutical composition for use in inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to claim 50.~~

3453. Use of thea compound or a pharmaceutically acceptable salt or isomer thereof according to any one of claims 1 to 32 infor the manufacture of a medicament for inhibiting autotaxin (ATX)~~, wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49~~.

~~54. Use of a pharmaceutical composition for the manufacture of a medicament for in inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to claim 50.~~

3555. An *in vitro* method of inhibiting autotaxin, the method comprising contacting a biological system comprising autotaxin with an effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to ~~49~~ 32 to inhibit autotaxin.

~~56. The method of claim 55, wherein the biological system is comprised in an *in vitro* sample.~~

~~57. The method of claim 55, wherein the biological system is *in vivo*.~~

~~58. A method of inhibiting autotaxin in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, or a pharmaceutical composition according to claim 50.~~

~~59. A method of treating an ATX-related indication in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, or a pharmaceutical composition according to claim 50.~~

~~60. The method of claim 59, wherein the ATX-related indication is selected from an inflammatory disease, autoimmune disease, proliferative disease, cancer, and fibrosis.~~

~~61. The method of claim 60, wherein the fibrosis occurs in the liver.~~

3662. A compound for use in inhibiting autotaxin (ATX) or treating an ATX-related indication, wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 32~~49.~~

~~63. A pharmaceutical composition for use in inhibiting autotaxin (ATX)~~, or a~~wherein the~~ pharmaceutical composition is according to claim 33~~50~~.

37~~64~~. Use of the~~a~~ compound or a pharmaceutically acceptable salt or isomer thereof according to any one of claims 1 to 32 in~~for~~ the manufacture of a medicament for treating an ATX-related indication~~, wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49~~.

~~65. Use of a pharmaceutical composition for the manufacture of a medicament treating an ATX-related indication, wherein the pharmaceutical composition is according to claim 50.~~

38~~66~~. The use of claim 37~~64 or 65~~, wherein the ATX-related indication is selected from an inflammatory disease, autoimmune disease, proliferative disease, cancer, and fibrosis.

39~~67~~. The use of claim 38~~66~~, wherein the fibrosis occurs in the liver.

40~~68~~. A compound of formula (II):



(II)

or a pharmaceutically acceptable salt or isomer thereof,

wherein:

Z^1, Z^2, and Z^3 are independently selected from C-R^1 and N;

R^{20} and R^{21} are each independently selected from H, and optionally substituted -(C_1-C_6)alkyl; or R^{20} and R^{21} together with the boron atom to which they are attached from an optionally substituted heterocycle;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C_1-C_6)alkyl and optionally substituted -(C_1-C_6)alkoxy;

Y is selected from S, O, and N-R^2, wherein R^2 is selected from -H, and optionally substituted -(C_1-C_6)alkyl;

R^7 is selected from H-, and optionally substituted (C_1-C_6)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C_1-C_6)alkyl;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C_1-C_6)alkoxy, -NH_2, substituted amino, optionally substituted -(C_1-C_6)alkyl-NH_2 and optionally substituted -(C_1-C_6)alkyl; and

n is 0, 1, 2, 3, 4, or 5.

~~69. The compound of claim 68, wherein the compound is:~~



~~.~~

41~~70~~. A compound of formula (III):



(III)

or a pharmaceutically acceptable salt or isomer thereof,

wherein:

X^1, X^2, and X^3 are independently selected from C-R^1 and N;

Z^1, Z^2, and Z^3 are independently selected from C-R^1 and N;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C_1-C_6)alkyl and optionally substituted -(C_1-C_6)alkoxy;

Y is selected from S, O, and N-R^2, wherein R^2 is selected from -H, and optionally substituted -(C_1-C_6)alkyl;

R^{3a} is selected from optionally substituted R^4-C(O)-(C_1-C_3)alkyl-, R^4C(O)-, halogen, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6HC-, and R^5R^6N-;

R^4 is selected from H_2N-, HO-, R^5R^6N-, optionally substituted (C_1-C_{10})alkyl-, optionally substituted (C_1-C_{10})alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C_1-C_6)alkylene-, and optionally substituted heterocycle-(C_1-C_6)alkylene-;

R^5 and R^6 are independently selected from H-, H_2N-, HO-, optionally substituted (C_1-C_{10})alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted R^4C(O)-(C_1-C_{10})alkyl-, R^4C(O)-, R^4-, and substituted amino;

or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;

R^7 is selected from H-, and optionally substituted (C_1-C_6)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C_1-C_6)alkyl;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C_1-C_6)alkoxy, -NH_2, substituted amino, optionally substituted -(C_1-C_6)alkyl-NH_2 and optionally substituted -(C_1-C_6)alkyl; and

n is 0, 1, 2, 3, 4, or 5.

42~~71~~. The compound of claim 41~~70~~, wherein the compound is:



(128),



(129),



(130),



(131),



(132),



(134),



(135),



(136),


(137),

(138),

(139),

(140),

(141),

(142),

(143),

(144),

(145),

(146),

(147),

(148), and



(149).